One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
bluebird bio logo
bluebird bio BLUE
report update icon

Quarterly report 2025-Q1
added 05-16-2026

bluebird bio Income Statement 2024-2010 | BLUE

Brief overview of revenue and earnings at bluebird bio

The figures are compared over a five-year interval. bluebird bio reported revenue of $44.7 million in 2019 and $83.8 million by 2024. The cumulative result was +87.6%, corresponding to roughly 13.4% per year. The pace indicates confident and sustained business growth.

The gross result shifted from $41.7 million to −$5.6 million, or −113.4%. Costs absorbed a larger share of revenue over the period. The gross margin was 93.3% at the start and −6.6% at the end. The margin decline reflects a less favorable sales-and-cost structure.

EBITDA was −$795 million at the beginning and −$210 million at the end of the period (+73.6%). Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of −1778.8% and −250.8%. The company improved its ability to convert sales into EBITDA.

Comparing the endpoints shows a move from −$790 million to −$241 million. The loss reduction is constructive, but the recovery is incomplete.

What the figures show

The results contain several connected negative signals. The strongest signals are a larger revenue base, improving net profitability and positive operating leverage. The overall view is constrained by limited operating profitability, weaker gross profitability and a low gross margin. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement bluebird bio

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

- 3.35 M 354 M 416 M 1.25 B 4.54 B 6.77 B 8.87 B 2.56 B 1.43 B 2.47 B 280 M - - -

Shares

9.69 M 5.49 M 78.6 M 68.9 M 62.2 M 55.2 M 52 M 43.5 M 37.3 M 34.7 M 26.5 M 12.6 M - - -

Historical Prices

- 0.61 4.51 6.04 20.1 46.8 101 130 56.8 29.9 61.7 16.5 - - -

Net Income

-241 M -212 M -230 M -819 M -619 M -790 M -556 M -336 M -264 M -167 M -48.7 M -25.3 M -23.7 M -15.6 M -

Revenue

83.8 M 29.5 M 3.6 M 3.66 M 251 M 44.7 M 54.6 M 35.4 M 6.16 M 14.1 M 25.4 M 20.2 M 340 K 882 K -

Cost of Revenue

89.4 M 33.5 M 10.1 M - - 2.98 M 885 K 1.53 M - - - - - - -

Gross Profit

-5.57 M -4.03 M -6.48 M - - 41.7 M 53.7 M 33.9 M - - - - - - -

Operating Income

-270 M -244 M -250 M -591 M -559 M -563 M -572 M -332 M -268 M -169 M -60.6 M -24.9 M -23.7 M -15.1 M -

Interest Expense

44.2 M 38.7 M 6.32 M 27.7 M -6.88 M -9.98 M 1.96 M -1.27 M -71 K 723 K 120 K -403 K 46 K -456 K -

EBITDA

-210 M -216 M -242 M -586 M -554 M -795 M -552 M -319 M -254 M -159 M -56.2 M -24 M -23.4 M -14.9 M -

Operating Expenses

- - - - - 854 M 623 M 367 M 270 M 180 M 85.8 M 45.1 M 24.1 M 16 M -

General and Administrative Expenses

168 M 166 M 140 M 210 M 240 M 271 M 174 M 93.6 M 65.1 M 46.2 M 23.2 M 14.1 M 6.85 M 4.62 M -

All numbers in USD currency

Quarterly Income Statement bluebird bio

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

9.75 M 9.73 M 194 M 194 M 9.66 M 193 M 109 M 109 M 103 M 82.9 M 81.5 M 73.8 M 73.7 M 71.1 M 68.6 M 67.5 M 67 M 66.4 M 66.3 M 60.4 M 55.6 M 55.4 M 55.3 M 55.2 M 55 M 54.7 M 53.3 M 50.2 M 49.9 M 49.4 M 45.6 M 41 M 40.8 M 40.7 M 37.2 M 37 M 36.9 M 36.9 M 36.4 M 33 M 32.6 M 32.3 M 28.1 M 24.5 M 24.1 M 23.9 M 23.6 M 2.15 M 328 K 309 K 275 K 252 K - - - - -

Net Income

-29.1 M - -60.8 M -81.4 M -69.8 M - -87.2 M -62.8 M 18.9 M - -76.5 M -100 M -122 M -155 M -217 M -242 M -206 M -200 M -195 M -21.5 M -203 M -223 M -206 M -196 M -164 M -149 M -145 M -146 M -115 M -117 M -78.8 M -70.9 M -68.7 M -71.4 M -77 M -58.8 M -56.3 M -47.3 M -42.9 M -51.8 M -24.8 M -19.5 M -17 M -1.53 M -10.6 M -8.08 M -6.11 M -4.58 M -6.54 M -9 M -5.04 M -4.56 M -5.07 M - - - -

Revenue

38.7 M - 10.6 M 16.1 M 18.6 M - 12.4 M 6.89 M 2.38 M - 71 K 1.52 M 1.94 M 1.61 M 1.02 M 143 K 894 K - - - - 10 M 8.91 M 13.3 M 12.5 M 19.2 M 11.5 M 7.85 M 16 M 4.17 M 7.71 M 16.7 M 6.83 M 1.55 M 1.55 M 1.55 M 1.5 M 1.47 M 1.32 M 4.94 M 6.34 M 6.39 M 6.36 M 6.34 M 6.34 M 6.34 M 6.38 M 6.33 M 1.13 M 85 K 85 K 85 K 85 K - - - -

Cost of Revenue

12.2 M - 11.8 M 28.9 M 25.9 M - 9.13 M 6.7 M 5.51 M - - 1.74 M 8.31 M - 19.4 M 15.3 M 576 K - 1.32 M 1.55 M 1.02 M - 862 K 613 K 430 K - 29 K 21 K 17 K - 1.1 M 420 K - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

26.5 M - -1.17 M -12.8 M -7.29 M - 3.27 M 193 K -3.13 M - 71 K -226 K -6.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-24.6 M - -66.9 M -88.4 M -78.7 M - -96 M -71.7 M 10.7 M - -84.8 M -107 M -120 M -136 M -154 M -155 M -146 M -139 M -132 M -144 M -144 M -231 M -210 M -203 M -171 M -157 M -150 M -149 M -117 M -117 M -77.7 M -67.8 M -69.9 M -72.3 M -78.1 M -60 M -57.4 M -49 M -43.1 M -52 M -24.9 M -19.6 M -17 M -13.3 M -10.7 M -8.12 M -6.16 M -4.19 M -6.48 M -8.96 M -5.02 M -4.6 M -5.14 M - - - -

Interest Expense

769 K - 10.2 M 9.64 M 11.2 M - 4.31 M 3.75 M 4.27 M - 7.88 M 7.09 M -1.91 M - 1.34 M -1.09 M 24.3 M - -6.69 M 1.55 M -4.45 M - -4.3 M -2.94 M -3.39 M - -252 K 182 K 115 K - 8 K -834 K -355 K - 937 K -76 K 961 K - 263 K 228 K 139 K - -20 K 11 K 59 K - 44 K -389 K -63 K - -17 K 37 K - - - - -

EBITDA

-9.06 M - - - -63.2 M - - - 16.9 M - -81 M -107 M -119 M -136 M -137 M -155 M -141 M -139 M -117 M -134 M -140 M -231 M -198 M -195 M -167 M -157 M -137 M -140 M -113 M -117 M -67.8 M -61.5 M -67.1 M -72.3 M -71 M -55.2 M -55.1 M -49 M -37.7 M -48.5 M -23.2 M -19.6 M -14.5 M -12.3 M -10.2 M -8.12 M -5.55 M -3.89 M -6.34 M -8.96 M -4.82 M -4.47 M -5.14 M - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - 176 M 161 M 156 M 133 M 121 M 85.4 M 84.5 M 76.7 M 73.9 M 79.7 M 61.5 M 58.9 M 50.4 M 44.5 M 57 M 31.3 M 26 M 23.4 M 19.7 M 17 M - - - - - - - - - - - -

General and Administrative Expenses

30.3 M - 39.8 M 50.4 M 46.3 M - 40.8 M 40.5 M 37.5 M - 33.4 M 36.7 M 36.1 M - 42.2 M 78.6 M 63.6 M - 68 M 68.6 M 73.2 M - 66.2 M 68.6 M 60.3 M - 44.5 M 41.2 M 34.9 M - 23 M 21.2 M 20.3 M - 14.6 M 18.4 M 16 M - 13.7 M 10.7 M 7.34 M - 6.65 M 5.74 M 5.54 M - 3.84 M 3.28 M 2.32 M - 1.61 M 1.33 M - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company bluebird bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.12 0.88 % $ 7.05 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.04 1.36 % $ 104 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.8 2.51 % $ 3.52 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 55.9 0.22 % $ 7.48 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.68 1.65 % $ 10.5 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.53 3.93 % $ 1.83 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.63 0.64 % $ 44.3 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 3.53 9.81 % $ 8.23 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.62 3.05 % $ 206 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 21.78 7.39 % $ 1.25 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 24.17 5.8 % $ 1.43 B usaUSA
Xencor Xencor
XNCR
$ 22.85 2.61 % $ 1.7 B usaUSA
Annexon Annexon
ANNX
$ 3.41 1.09 % $ 529 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.76 0.54 % $ 2.9 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.07 0.03 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 13.28 1.16 % $ 16 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.28 5.1 % $ 746 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 499.74 0.08 % $ 128 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.25 0.42 % $ 13.7 B danmarkDanmark
Axon Enterprise Axon Enterprise
AXON
$ 390.29 2.15 % $ 30.5 B usaUSA
AbbVie AbbVie
ABBV
$ 285.42 0.71 % $ 505 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.72 2.35 % $ 97.8 M usaUSA
Altimmune Altimmune
ALT
$ 2.2 2.16 % $ 194 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.22 2.39 % $ 809 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.84 0.87 % $ 1.06 B usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
$ 1.24 5.43 % $ 108 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 12.93 2.64 % $ 779 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.96 4.0 % $ 183 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.28 3.25 % $ 402 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 23.19 0.04 % $ 734 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 4.52 4.39 % $ 60.2 M usaUSA
Curis Curis
CRIS
$ 0.41 1.4 % $ 5.4 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 9.52 5.01 % $ 752 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA